NPCE Stock Quote Price and Forecast | CNN

NPCE

NeuroPace, Inc.

Key terms

NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Key terms

Smart score

Apr 04 9:20am ET ‘Time to Hit Buy,’ Says Wells Fargo About These 2 Stocks by TipRanks Mar 07 1:01am ET Neuropace, Inc.’s New Economy & Political Environment Risk – A Cause for Worry? by TipRanks Mar 06 11:15pm ET NeuroPace Secures Buy Rating from Analyst Mike Kratky Amid Positive Revenue Guidance and Growth Drivers by TipRanks Mar 06 9:13am ET NeuroPace price target raised to $13 from $9 at Morgan Stanley by TipRanks Mar 06 8:54am ET NeuroPace price target raised to $20 from $17 at Lake Street by TipRanks Mar 06 6:28am ET NeuroPace Financial Analysis: Hold Rating Maintained Amid Growth and Spending Concerns by TipRanks Mar 05 4:17pm ET NeuroPace sees FY24 revenue $73M-$77M, consensus $74.6M by TipRanks Mar 05 4:15pm ET NeuroPace reports Q4 EPS (23c), consensus (31c) by TipRanks Feb 22 6:40am ET NeuroPace price target raised to $16 from $9 at Wells Fargo by TipRanks Feb 08 4:56am ET NeuroPace Announces Chief Legal Officer Irina Ridley’s Departure by TipRanks Jan 30 6:17am ET NeuroPace initiated with an Outperform at Leerink by TipRanks Jan 24 8:30am ET Three new option listings on January 24th by TipRanks Jan 09 8:54am ET NeuroPace price target raised to $17 from $12 at Lake Street by TipRanks Jan 09 5:11am ET Analysts Offer Insights on Healthcare Companies: NeuroPace (NPCE), Alignment Healthcare (ALHC) and 10x Genomics (TXG) by TipRanks Jan 08 7:15am ET NeuroPace sees FY23 revenue $64.9M-$65.4M, consensus $63.01M by TipRanks Jan 08 7:15am ET NeuroPace reports preliminary Q4 revenue $17.5M-$18M, consensus $15.79M by TipRanks

No recent press releases are available for NPCE

1-year income & revenue

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.

Scott Olson/Getty Images

Trump’s stock tumbles again after Truth Social announces it’s getting into streaming

Tim Wren, chief commercial officer for BSI Group, right, presents Kristalina Georgieva, chief executive officer of the World Bank Group, second right, with ISO 20121 certification for sustainable event management at an event during the spring meetings of the International Monetary Fund (IMF) and World Bank in Washington, DC, US, on Monday, April 15, 2024. The IMF and World Bank spring meetings in Washington are expected to draw thousands of delegates, observers and journalists from the fund's 190 member countries. Photographer: Samuel Corum/Bloomberg via Getty Images

Samuel Corum/Bloomberg/Getty Images

Geopolitical strife is roiling Wall Street. Here’s what investors are watching

Donald Trump might no longer own a majority of TMTG after a new public share offering.

Joe Raedle/Getty Images

Trump stock tanks after announcing massive share sale

1040 US Individual Income Tax Return Form

Nora Carol Photography/Moment RF/Getty Images

Three ways investors can minimize their tax payments